Paulus Stoffels - 01 Jul 2026 Form 4 Insider Report for TAKEDA PHARMACEUTICAL CO LTD (TAK)

Reporting relationship: Director
Issuer ticker: TAK
Reported as of: 01 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 06 Jul 2026, 18:11:16 UTC
Prior SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ /s/ Samuel Ntonme, by power of attorney, for Paul Stoffels

Key filing fact

Paulus Stoffels filed Form 4 for TAKEDA PHARMACEUTICAL CO LTD (TAK) on 06 Jul 2026.

Key facts

This page summarizes Paulus Stoffels's Form 4 filing for TAKEDA PHARMACEUTICAL CO LTD (TAK).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 06 Jul 2026, 18:11.

Change

Previous filing in this sequence was filed on 06 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001559387 Primary reporting owner

Stoffels Paulus

Relationship: Director
Address: C/O TAKEDA PHARMACEUTICAL COMPANY, 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO, JAPAN
Signature: /s/ /s/ Samuel Ntonme, by power of attorney, for Paul Stoffels
Signature date: 06 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TAK transaction

Ordinary Shares

Award

Transaction value
Shares: +3,800
Change %
Price: $0.000000^*
Shares after: 3,800
Date: 01 Jul 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TAK transaction Derivative

Tax Obligation Award

Award

Transaction value
Shares: +1,307
Change %
Price: $0.000000^*
Shares after: 1,307
Date: 01 Jul 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 1,307
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American Depositary Shares following vest. The RSUs vest on June 1, 2029.

Footnote F2

Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares.